Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
601 to 620 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| R01CA229510 | Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy | 1 | 2023 |
| R01CA232433 | Chemoprevention of lung cancer by targeting lonidamine to mitochondria | 1 | 2023 |
| R01CA233490 | Genetic and Epigenetic Biomarkers for B-cell Lymphoma | 1 | 2023 |
| R01CA233719 | Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease Risk | 1 | 2023 |
| R01CA240983 | Targeting Neoantigens in Triple Negative Breast Cancer | 1 | 2023 |
| R01CA241559 | Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation | 1 | 2023 |
| R01CA241762 | Linking insertional mutagenesis and cell function to improve CAR T cell therapy | 1 | 2023 |
| R01CA243543 | Cellular Immunotherapy of Ovarian Cancer | 1 | 2023 |
| R01DE028282 | Role of EphB4-ephrin-B2 interaction in regulating crosstalk between cancer cell and vascular tumor microenvironment in head and neck cancer | 1 | 2023 |
| R01DE028420 | Mechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCC | 1 | 2023 |
| R01DE028563 | Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC | 1 | 2023 |
| R01DK119202 | Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis Models | 1 | 2023 |
| R01DK127497 | Determining the mechanism of IFIH1 disease-associated variants on beta-cell and immune responses in Type 1 diabetes | 1 | 2023 |
| R01DK130425 | Experimental and natural SARS-CoV-2 infection of the human pancreas | 1 | 2023 |
| R01ES028269 | Ozone, oxysterols, and lung inflammation | 1 | 2023 |
| R01HG011239 | Mapping gene-by-environment interactions using multiplexed single cell RNA-sequencing | 1 | 2023 |
| R01HL121093 | Pathogenesis of autoimmune valvular carditis | 1 | 2023 |
| R01HL148337 | The Cytokine Suppressor CIS in Giant Cell Pneumonitis | 1 | 2023 |
| R01HL148338 | Reversal of Heart Failure: Role of Vascular Recovery | 1 | 2023 |
| R01NS110087 | Tet2 regulation and function in glioma cell phenotype reprogramming | 1 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=31